Except for traditional treatment using BCG bladder irrigation, recently, immunotherapy targeting immune checkpoints CTLA-4 and PD-1/PD-L1 has been applied to treat early-stage bladder cancer, achieving satisfactory clinical efficacy (7, 38, 39). This evidence concerns the gene PDCD1 and urinary bladder cancer.